Holders — by stockHoldings — by fund
Lynx1 Capital Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001910456
$865.5M
disclosed book value
27
positions
41.2%
largest position share
Positions, as of 2026-06-30
top 27 of 27 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | GH RESEARCH PLC | 13.3M | $356.5M | 41.2% |
| 2 | CGEMCULLINAN THERAPEUTICS INC | 9.0M | $163.2M | 18.9% |
| 3 | STOKSTOKE THERAPEUTICS INC | 4.0M | $132.1M | 15.3% |
| 4 | AGIOAGIOS PHARMACEUTICALS INC | 3.4M | $126.5M | 14.6% |
| 5 | CCCCC4 THERAPEUTICS INC | 7.3M | $34.2M | 4% |
| 6 | KRROKORRO BIO INC | 1.5M | $20.3M | 2.3% |
| 7 | TCRXTSCAN THERAPEUTICS INC | 8.0M | $7.9M | 0.9% |
| 8 | DTILPRECISION BIOSCIENCES INC | 950,466 | $7.5M | 0.9% |
| 9 | NEUPNEUPHORIA THERAPEUTICS INC | 875,328 | $3.8M | 0.4% |
| 10 | PASGPASSAGE BIO INC | 673,759 | $3.3M | 0.4% |
| 11 | CGONCG ONCOLOGY INC | 31,391 | $2.2M | 0.3% |
| 12 | PLRXPLIANT THERAPEUTICS INC | 1.8M | $2.0M | 0.2% |
| 13 | TRDAENTRADA THERAPEUTICS INC | 178,606 | $1.3M | 0.2% |
| 14 | MNLOUSDVYNE THERAPEUTICS INC | 1.6M | $1.1M | 0.1% |
| 15 | PROQR THRAPEUTICS N V | 521,413 | $969,828 | 0.1% |
| 16 | TRAWTRAWS PHARMA INC | 559,470 | $471,801 | 0.1% |
| 17 | FHTXFOGHORN THERAPEUTICS INC | 61,588 | $300,549 | 0% |
| 18 | DNLIDENALI THERAPEUTICS INC | 11,658 | $299,844 | 0% |
| 19 | XNCRXENCOR INC | 18,194 | $292,923 | 0% |
| 20 | ABSIABSCI CORPORATION | 21,245 | $246,230 | 0% |
| 21 | HOWLWEREWOLF THERAPEUTICS INC | 657,786 | $236,737 | 0% |
| 22 | IMMATICS N.V | 23,236 | $235,381 | 0% |
| 23 | AVTXAVALO THERAPEUTICS INC | 10,100 | $186,648 | 0% |
| 24 | BOLTBOLT BIOTHERAPEUTICS INC | 30,800 | $118,580 | 0% |
| 25 | NUVBNUVATION BIO INC | 16,029 | $91,045 | 0% |
| 26 | EPRXEUPRAXIA PHARMACEUTICALS INC | 10,000 | $66,100 | 0% |
| 27 | IKTINHIBIKASE THERAPEUTICS INC | 20,000 | $40,600 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.